Title:High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
Volume: 16
Issue: 4
Author(s): Yuao Deng, Longyang Liu, Weifeng Feng, Zhongqiu Lin, Yingxia Ning*Xin Luo*
Affiliation:
- Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120,China
- Department of Gynecology and Obstetrics, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, 510630,China
Keywords:
Expression of MYL9, clinical prognosis, Epithelial Ovarian Cancer, biomarkers, linicopathological parameters,
paratumor tissues.
Abstract:
Background: The prognosis of Epithelial Ovarian Cancer (EOC) is poor, but the prognostic
biomarkers are neither sensitive nor specific. Therefore, it is very important to search novel
prognostic biomarkers for EOC.
Objectives: The present study aimed to investigate Myosin Light Chain 9(MYL9) expression in
Epithelial Ovarian Cancer (EOC) tissues (including paraffin-embedded and fresh tissue samples)
and its relationship with clinicopathological characteristics, as well as its potential prognostic value
in patients with EOC.
Methods: Between March 2009 and December 2018, all of 184 paraffin-embedded cancer tissues
from patients with EOC and 41 paratumor tissues, pathologically confirmed at the Memorial Hospital
of Sun Yat-sen University and Integrated Hospital of Traditional Chinese Medicine, Southern
Medical University, were collected for the present study and were assessed for MYL9 protein expression
patterns using Immunohistochemistry (IHC). Furthermore, from August 2013 to November
2019, 16 fresh EOC tissues and their paired paratumor tissues, pathologically confirmed at the
Integrated Hospital of Traditional Chinese Medicine, Southern Medical University were analyzed
using Reverse-Transcription Quantitative PCR (RT-qPCR) to detect MYL9 mRNA expression levels.
Results: The results showed that MYL9 expression was higher in cancer tissues compared with
that in paratumor tissues, and MYL9 overexpression was associated with shorter Recurrence Free
Survival (RFS) and Overall Survival (OS) of EOC patients. Furthermore, multivariate Cox model
analysis indicated that MYL9 overexpression was an independent poor survival prediction in patients
with EOC.
Conclusion: MYL9 is upregulated in EOC and may serve as a useful patent of prognostic biomarker
in EOC, and it may demonstrate an important value for the clinical treatment and supervision of
patients with EOC.